Filing Flows › 10x Genomics (TXG) › Q1 2026
10x Genomics (TXG) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 8, 2026
10x Genomics (TXG) reported revenue of $151M for the first quarter 2026 (Q1 2026), -3% from a year earlier and -9% from the quarter before. Operating margin was -11.3%, net loss $13.5M (8.9% of revenue).
10x Genomics, Q1 2026: revenue $151M (-3% year over year), operating margin -11.3%, net loss $13.5M, operating cash flow $26.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $151M | -9% | -3% |
| Operating profit | −$17.0M | — | — |
| Net earnings | −$13.5M | — | — |
| Operating cash flow | $26.1M | -36% | -24% |
| Free cash flow | $24.5M | -37% | -24% |
What changed
Revenue was $150.8M in Q1 2026, down 3% year over year and down 9% from the previous quarter. Single Cell was the largest line at 59% of revenue. License and royalty revenue lost $16.1M year over year (down 94%), 399% of the total change.
Gross margin was 70.4%, up 2.3 points from Q1 2025. Operating costs exceeded revenue by $17.0M, an operating margin of -11.3%. Operating expenses fell 15% while revenue fell 3%. The quarter ended with a net loss of $13.5M, narrower than the previous quarter's $16.3M loss. Non-operating items added $4.2M, -33% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $26.1M (down 24% year over year). Non-cash charges added back $10.0M of depreciation and amortization and $22.6M of share-based compensation. Working capital and other items added $7.0M. Capital expenditures of $1.6M left free cash flow of $24.5M.
Questions
What was 10x Genomics' revenue in the first quarter 2026?
10x Genomics (TXG) reported revenue of $151M for the first quarter 2026 (Q1 2026), -3% from a year earlier and -9% from the quarter before.
Was 10x Genomics profitable in the first quarter 2026?
Operating loss was $17.0M (-11.3% of revenue) and net loss $13.5M.
Source: 10x Genomics 10-Q on SEC EDGAR.